Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in manufacturing and marketing, and is rolling out the first of its innovative syringe products.
The syringe market is worth over $6 billion. The pandemic raised public awareness about the importance of a strong and steady syringe supply. Now, pharmaceutical and manufacturing companies are turning to next-generation solutions like prefillable syringes, which deliver medicine utilizing enhanced features and benefits that will support a lower cost of total ownership (TCO) for healthcare companies.
Sharps Technology is a medical device and drug delivery company focusing on specialized and prefillable syringes. Public since April 2022, Sharps is looking to fulfill demand in the market and modernize syringe offerings through its line of polymer prefillable and ultra-low waste safety syringes. A year on from its IPO, Sharps can reflect on a series of robust company successes and exciting developments.
IPO, Manufacturing …
Full story available on Benzinga.com
